このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Caribou Biosciences 過去の業績

過去基準チェック /06

Caribou Biosciencesの収益は年間平均-30.8%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 52.9%割合で増加しています。

主要情報

-29.4%

収益成長率

29.9%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	56.3%
株主資本利益率	-39.8%
ネット・マージン	-372.8%
前回の決算情報	30 Jun 2024

Recent updates

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Sep 30

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Sep 06

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Jul 26

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Jul 03

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Jun 05

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Apr 18

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Apr 17

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Feb 15

Caribou Biosciences: Under The Radar With Catalysts Approaching

Feb 01

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Jan 10

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Nov 18

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Feb 24

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Oct 12

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Sep 16

Caribou Biosciences: Potential To Change CAR-T Landscape

Aug 01

Crispred CAR-T Cells In The Clinic

May 19

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 13

収支内訳

Caribou Biosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:CRBU 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
30 Jun 24	33	-123	46
31 Mar 24	33	-115	44
31 Dec 23	34	-102	38
30 Sep 23	35	-95	37
30 Jun 23	14	-111	37
31 Mar 23	15	-108	37
31 Dec 22	14	-99	38
30 Sep 22	13	-91	37
30 Jun 22	13	-85	34
31 Mar 22	11	-73	29
31 Dec 21	10	-67	24
30 Sep 21	8	-63	21
30 Jun 21	5	-50	17
31 Mar 21	12	-38	15
31 Dec 20	12	-34	14
31 Dec 19	6	-23	16

質の高い収益: CRBUは現在利益が出ていません。

利益率の向上: CRBUは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CRBUは利益が出ておらず、過去 5 年間で損失は年間30.8%の割合で増加しています。

成長の加速: CRBUの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CRBUは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: CRBUは現在利益が出ていないため、自己資本利益率 ( -33.58% ) はマイナスです。

Caribou Biosciences 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Insufficient new directors

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Caribou Biosciences Announces the Fda Has Granted Fast Track Designations to Cb-010 in Refractory Sle and to Cb-012 in Relapsed or Refractory Aml

Caribou Biosciences Appoints Tina Albertson as Chief Medical Officer

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Caribou Biosciences, Inc. Appoints Terri Laufer to Its Scientific Advisory Board

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Price target decreased by 16% to US$16.63

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Caribou Biosciences, Inc. Presents Encouraging Clinical Data from CB-010 Antler Phase 1 Trial in Second-Line Lbcl Patients At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

First quarter 2024 earnings: EPS misses analyst expectations

Caribou Biosciences, Inc., Annual General Meeting, Jun 13, 2024

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Price target decreased by 8.0% to US$20.25

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Chief Scientific Officer exercised options to buy US$212k worth of stock.

Caribou Biosciences: Under The Radar With Catalysts Approaching

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer

Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Consensus revenue estimates increase by 71%

Price target decreased by 7.8% to US$22.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board

Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Caribou Biosciences, Inc. Appoints Reigin Zawadzki as Chief People Officer

Consensus revenue estimates decrease by 19%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.4% to US$24.86

Price target decreased by 8.6% to US$25.14

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

New minor risk - Shareholder dilution

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Caribou Biosciences, Inc

Pomerantz Law Firm Announces the Filing of A Class Action Against Caribou Biosciences, Inc

Caribou Biosciences, Inc. Appoints Jason V. O'Byrne as Principal Accounting Officer

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

Chief Scientific Officer exercised options to buy US$206k worth of stock.

Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy and Fast Track Designations to Cb-010, an Allogeneic Anti-Cd19 Car-T Cell Therapy

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-Bcma Car-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences Presents Case Report on Long-Term Follow Up of First Patient Dosed in Phase 1 Antler Trial At the Lymphoma, Leukemia, & Myeloma Congress 2022

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Vice President of Finance & Controller recently sold US$108k worth of stock

Insider exercised options to buy US$314k worth of stock.

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Chief Scientific Officer exercised options and sold US$369k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caribou Biosciences: Potential To Change CAR-T Landscape

Caribou Biosciences, Inc. Announces Board Changes

Caribou Biosciences, Inc., Annual General Meeting, Sep 20, 2022

Caribou Biosciences, Inc.(NasdaqGS:CRBU) dropped from Russell 2000 Growth Index

Caribou Biosciences, Inc. Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress

Chief Scientific Officer exercised options to buy US$643k worth of stock.

Crispred CAR-T Cells In The Clinic

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy

Caribou Biosciences, Inc. Appoints David Johnson to its Board of Directors

過去基準チェック /06